Actionable news
All posts from Actionable news
Actionable news in HZNP: Horizon Pharma, Inc.,

The Sun May Not Rise At Horizon Pharma For Duexis

Horizon Pharma (NASDAQ:HZNP) recently announced the launch of Duexis, a combination of ibuprofen 800 mg and famotidine 26.6 mg, indicated for rheumatoid arthritis (RA) and osteoarthritis (OA). The Center of Disease Control estimates the prevalence of RA and OA at over 28 million Americans. For Horizon, the market potential for Duexis is substantial, but in reality, the market penetration may be disappointing. Duexis prevents one ulcer for every 10 patients when compared to ibuprofen alone, but the data does not indicate that it prevents gastrointestinal bleeding. In addition, there are market forces that may prevent Duexis from gaining any traction in the RA and OA space.

Ibuprofen and famotidine, the active ingredients in Duexis, are available in multiple strengths on the shelves of your local pharmacy or by prescription. Ibuprofen 200 mg is sold over-the-counter by various generic manufacturers and under the trade names of Motrin by Johnson & Johnson (NYSE:JNJ) and Advil by Pfizer (NYSE:PFE). Similarly, famotidine is also available over-the-counter in 10 and 20 mg tablets from various generic...